The fallout from AstraZeneca’s public clash with the DSMB of its U.S. Phase III trial will hurt the company individually more than biopharma as a whole. But the incident chips away at the broad goodwill...

Vir’s COVID mAb has produced some of the strongest data to date in high-risk outpatients, reducing hospitalization or death by 85% (p=0.002). Vir Biotechnology Inc. (NASDAQ:VIR) and partner GlaxoSmithKline...

AstraZeneca is the latest company to report that its COVID-19 vaccine seems to be working against new variants of the virus, just not quite as well. So far, that effect has been independent of the...

Vaxart Inc. (NASDAQ:VXRT) lost $13.81 (59%) to $9.52 Wednesday on preliminary Phase I data for VXA-CoV2-1. The data showed the vaccine did evoke CD8+ T cell and IgA responses but no detectable serum neutralizing antibodies....

Phase III data in The Lancet revealed Russian COVID-19 vaccine Sputnik V has efficacy on par with other leading vaccines across several groups: the full population, those who had not yet received a second dose, and the...

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...

December has been a busy month for Alzheimer’s therapies testing new hypotheses outside of amyloid, with the latest coming Wednesday from Novo Nordisk, which said it is taking semaglutide into Phase III...

The dizzying pace of COVID-19 vaccine readouts over the last three weeks is only going to accelerate over the next five. By the end of the year, three of the four leading vaccines are likely...

Investors and bankers believe specialist-backed SPACs could become a cyclical part of biotech’s fund-raising equation with some clear advantages over traditional IPOs for the right type of company. But...

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...